Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
暂无分享,去创建一个
Carlos Barrios | Toyoaki Hida | Keunchil Park | D. Gandara | F. Kabbinavar | F. Ciardiello | C. Barrios | S. Gadgeel | F. Barlesi | Daniel S Chen | M. Ballinger | A. Sandler | M. Kowanetz | T. Hida | Fabrice Barlesi | Keunchil Park | Fortunato Ciardiello | Marcin Kowanetz | David R Gandara | Shirish M Gadgeel | J. Leach | Jonathan Polikoff | Alan Sandler | D. Kowalski | H. Turna | Achim Rittmeyer | Daniel Waterkamp | Joachim von Pawel | Dariusz M Kowalski | Manuel Cobo Dols | Diego L Cortinovis | Joseph Leach | Fairooz Kabbinavar | Osvaldo Arén Frontera | Filippo De Marinis | Hande Turna | Jong-Seok Lee | Marcus Ballinger | Pei He | D. Cortinovis | J. Pawel | F. Marinis | Daniel S. Chen | A. Rittmeyer | D. Waterkamp | P. He | M. C. Dols | J. Polikoff | Jong-Seok Lee | O. A. Frontera | M. Dols
[1] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[2] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[3] Keunchil Park,et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial , 2016, The Lancet.
[4] Daniel S. Chen,et al. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] G. Freeman,et al. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions , 2010, Mucosal Immunology.
[6] H. Kohrt,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.
[7] G. Freeman,et al. The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo , 2011, The Journal of Immunology.
[8] D. Pardoll,et al. B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma. , 2008, Biochemical and biophysical research communications.
[9] F. Hirsch,et al. Postprogression Prolongation of Survival in EGFR-Mutated Lung Cancer: Reconciling the ASPIRATION and IMPRESS Trials. , 2016, JAMA oncology.
[10] G. Freeman,et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. , 2007, Immunity.
[11] S. Anand,et al. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. , 2010, Blood.
[12] G. Freeman,et al. The Novel Costimulatory Programmed Death Ligand 1/B7.1 Pathway Is Functional in Inhibiting Alloimmune Responses In Vivo , 2011, The Journal of Immunology.
[13] Axel Hoos,et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.
[14] I. Mellman,et al. Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.
[15] F. Hodi,et al. Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1 , 2012, Clinical Cancer Research.
[16] L. Sequist,et al. Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study. , 2015 .
[17] Y. Shentu,et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.
[18] M. Socinski,et al. Considerations for second-line therapy of non-small cell lung cancer. , 2008, The oncologist.
[19] Lieping Chen,et al. Inhibitory B7-family molecules in the tumour microenvironment , 2008, Nature Reviews Immunology.
[20] P. Hegde,et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.